Abstract 261P
Background
Ovarian germ cell tumour (GCT) is a potentially curable malignancy generally occurring in young females. The impact of various social stigmas on these women is profound especially among the lower socioeconomic classes from developing countries. The data on the epidemiology and potential challenges in management will help to fine-tune our approach.
Methods
A Retrospective analysis of ovarian GCTs treated at our institute from 2011 to 2017 was carried out. Our aim was to study the epidemiology, salient features and long-term outcomes in ovarian GCTs.
Results
There were 14 benign teratomas and 35 malignant tumours. 12 were mixed GCTs ,11 were dysgerminomas, 6 were yolk sac tumours, 5 were immature teratomas and there was 1 pure Choriocarcinoma. The median age at presentation for malignant tumours was 21.14years and for benign teratomas was 40 years. Pain was the presenting complaint in 74%, mass in 20% and 5%came with ascites. Bilaterality observed in 20%dysgerminoma,14%benign teratomas and 8%mixed tumours. Those with FIGO stage1 was 58% and 38% were stage3 at presentation. Mean size of dysgerminomas was 12cm and 14cm for non-dysgerminomas. Three cases diagnosed antenatally underwent LSCS along with definitive surgery at term and another patient underwent early MTP. Fertility sparing surgery was done in 63.4% benign and 60% of malignant cases. There was no indication for chemotherapy in 6 patients. Neoadjuvant chemotherapy was given for 4 patients and adjuvant for the rest(BEP). After chemotherapy 15%developed ovarian failure. Nausea, vomiting, diarrhoea and neutropenia were the common adverse events.6 patients defaulted after surgery. All dysgerminomas and teratomas achieved complete remission and the overall rate was 93.3%. Recurrence at 45month follow-up was 18% but zero for dysgerminoma. Most recurrences were within 2years (75%). OS during the period was 88.5%.
Conclusions
Malignant ovarian GCTs occur in younger females and benign ones more in the middle age. The long-term outcomes are generally excellent. Non-dysgerminoma histology, inadequate surgery and advanced stage are poor prognostic factors. The social stigmas associated with a diagnosis of cancer seemed to adversely impact the treatment compliance and long term follow up.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The presenting author.
Funding
Has not received any funding.
All authors have declared no conflicts of interest.
Resources from the same session
107P - The efficacy of adjuvant chemotherapy according to the risk classification of recurrence based on the systemic inflammatory markers in patients with colorectal cancer liver metastases
Presenter: Masatsune Shibutani
Session: Poster display session
Resources:
Abstract
108P - Influence of liver metastasis locations on overall survival in patients with colorectal cancer
Presenter: Takayuki Sone
Session: Poster display session
Resources:
Abstract
109P - 18F-FDG PET/CT textural features as predictors of outcomes in patients with primary advanced colorectal cancer
Presenter: Jing Yang
Session: Poster display session
Resources:
Abstract
110P - D3 lymph node dissection may be necessary in clinical stage I right colon cancer
Presenter: Woong Bae Ji
Session: Poster display session
Resources:
Abstract
111P - Is preoperative chemoradiotherapy necessary for all patients with upper rectal cancer: One center retrospective study
Presenter: Jasur Madyarov
Session: Poster display session
Resources:
Abstract
112P - A retrospective analysis of the association between perioperative, post adjuvant carcinoembryonic antigen level and prognosis in stage III colorectal cancer
Presenter: Ryotaro Kozuki
Session: Poster display session
Resources:
Abstract
113P - Dicer contributes to chemoresistance in colorectal cancer via regulating a set of miRNAs and their downstream mRNAs
Presenter: Liang-Yi Hung
Session: Poster display session
Resources:
Abstract
114P - Efficacy and safety of the combination of bevacizumab with raltitrexed-based chemotherapy as second-line therapy in patients with metastatic colorectal cancer (mCRC): An interim analysis of a multicenter phase II trial
Presenter: Jun Zhu
Session: Poster display session
Resources:
Abstract
115P - Expression of Ki-67 as a prognostic factor in patients with colorectal cancer
Presenter: Kuantkan Zhabagin
Session: Poster display session
Resources:
Abstract
116P - Clinical significance and converionrate relevance of RAS genetic mutation analysis for unresectable colorectal liver metastases: A single-center retrospective study
Presenter: Meiling Ji
Session: Poster display session
Resources:
Abstract